Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen

Teijin Pharma President Hiroshi Uno Teijin Pharma has revised up its FY2015 sales target in Japan for the hyperuricemia drug Feburic (febuxostat) to “20 billion yen or more” from the previous “20 billion yen,” President Hiroshi Uno revealed in a...read more